(Q38129960)

29 August 2017

title

Emerging treatments for chronic constipation (English)

1 reference

29 August 2017

Vineet S Gudsoorkar

1

1 reference

29 August 2017

Eamonn M M Quigley

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

20 August 2013

1 reference

Expert Opinion on Emerging Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

18

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

365-373

1 reference

Chronic constipation in the elderly

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Chronic constipation: a survey of the patient perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Quality of life in children and adults with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Psychological morbidity in women with idiopathic constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

A clinical approach to constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Mechanisms of constipation in older persons and effects of fiber compared with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Systematic review on the management of chronic constipation in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Oral bisacodyl is effective and well-tolerated in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Lactulose Syrup Assessed in a Double-Blind Study of Elderly Constipated Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Pharmacological management of constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Cisapride: what can we learn from the rise and fall of a prokinetic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Prucalopride: safety, efficacy and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Effects of lubiprostone on human uterine smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Efficacy and safety of lubiprostone in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Chloride channels as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Guanylate cyclase-C receptor activation: unexpected biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Two randomized trials of linaclotide for chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Elobixibat for the treatment of constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

Sacral nerve stimulation for constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.831068

10.1517/14728214.2013.831068

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference